Stay updated on ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.

Latest updates to the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page
- Check2 days agoChange DetectedThe website’s footer revision indicator changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check9 days agoChange DetectedThe ClinicalTrials.gov record for the ALT-803 and nivolumab study is displayed with detailed study design, participant criteria, locations, outcome measures, and record history. It also includes links to the study protocol and informed consent form.SummaryDifference61%

- Check16 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedA site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page. The site revision label also changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study page for NCT02523469 now displays a 403 Forbidden error with a minimal header and a Home link, replacing the previously available trial content and documents.SummaryDifference20%

Stay in the know with updates to ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.